Paper Details

  1. Home
  2. Paper Details

Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports.

Author: AronsonJeffrey K, HeneghanCarl J, LeeJoseph J, MahtaniKamal R, OnakpoyaIgho J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Naltrexone-bupropion significantly reduced body weight by a small amount but significantly increased the risk of adverse events. Participants taking naltrexone-bupropion achieved a 2.53 kg reduction in baseline body weight compared to placebo, but also experienced a higher risk of adverse events, serious adverse events, and discontinuation due to adverse events.
Paper Details　
Original Abstract of the Article :
AIMS: To compare the benefits and harms of naltrexone-bupropion using evidence from clinical study reports. METHODS: We searched Food and Drug Administration and European Medicines Agency websites, PubMed, and Clinicaltrials.gov (May 2016) to identify pivotal trials; we then sent a freedom of infor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098870/

データ提供：米国国立医学図書館（NLM）

Naltrexone-bupropion: A New Weapon in the Fight Against Obesity

Obesity is a growing health concern worldwide, and finding effective treatments has become a critical mission. This systematic review and meta-analysis examines the efficacy and safety of naltrexone-bupropion (Mysimba) in managing obesity. The researchers, like intrepid explorers charting a course through a vast and uncharted territory, meticulously analyzed data from clinical studies to evaluate the effectiveness of this new medication. The results reveal that naltrexone-bupropion can be a valuable tool in the fight against obesity, but it's important to consider its potential side effects.

Naltrexone-bupropion: A Mixed Bag of Benefits and Risks

The study found that naltrexone-bupropion significantly increased the likelihood of achieving a 5% or greater reduction in body weight compared to placebo. However, the researchers also noted a significant increase in the risk of adverse events. This finding, like a mirage in the desert, highlights the importance of careful consideration of both the benefits and risks associated with this medication.

Navigating the Landscape of Weight Management

This research, like a guidebook for navigating a treacherous desert, provides valuable insights into the complex landscape of weight management. It reminds us that there is no one-size-fits-all solution, and each individual must weigh the potential benefits and risks of different treatment options. By understanding the nuances of weight management, we can make informed decisions about our health and well-being.

Dr. Camel's Conclusion

This research, like a camel caravan traversing a vast and unforgiving desert, highlights the potential of naltrexone-bupropion as a new weapon in the fight against obesity, but cautions us to proceed with careful consideration of its potential side effects.

Date :
  1. Date Completed 2021-07-28
  2. Date Revised 2021-07-28
Further Info :

Pubmed ID

31918448

DOI: Digital Object Identifier

PMC7098870

Related Literature

Article Analysis
・Side Effects of naltrexone and bupropion
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.